Newsroom

Newsroom

Spatially defining immune populations with MultiOmyx™ to predict clinical efficacy

Blog
Read More

NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer

Press Release
Read More

Circulating tumor DNA (ctDNA) monitoring in breast cancer patients receiving neoadjuvant palbociclib and endocrine therapy. A secondary analysis of the NeoRHEA phase 2 study

Literature
Read More

LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer

Literature
Read More

A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD)

Literature
Read More

Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial

Literature
Read More

Multimodal detection in plasma of molecular residual disease (MRD) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC)

Literature
Read More

Validation of recurrence prediction using circulating tumor DNA in patients with curatively treated early stage non-small cell lung cancer

Literature
Read More

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients